J. Robert Hall

LymphoSign, Inc. develops drugs for the cancer treatment. It also develops drugs acting on signaling pathways involved in the progression of acute leukemias, lymphomas and solid tumors. The company was founded by Chaim Roifman in 2000 and is headquartered in Markham, Canada.

GrowthWorks Capital Ltd. (GrowthWorks) is a venture capital firm founded in 1992 by David Levi. The firm is headquartered in Vancouver, Columbia with additionaal offices in Saskatchewan, Manitoba, New Brunswick, Newfoundland, Nova Scotia, and Ontario.

BDC Venture Capital (BDC Venture Capital) is a venture capital firm founded in 1975. The firm is headquartered in Québec, Canada.

Dynacon, Inc. designed and integrated pre-analytical microbiology automation solutions. The company was founded in 1975 and was headquartered in Mississauga, Canada.

Aurelium BioPharma Inc., develops therapeutics and diagnostics for the treatment of drug-resistant cancers. The company has developed several diagnostic tests for the detection of breast, ovarian as well as drug-resistant cancers. The firm has a strong drugable pipeline of novel targets and complimentary diagnostic products that are utilized in its strategic collaborations and out-licensing efforts. The company was founded in May 1998 and is headquartered in Laval, Canada.

Business Development Bank of Canada provides commercial banking services. It offers business loans and consulting services to help Canadian businesses grow, both at home and abroad. The firm also offers a full spectrum of specialized financing, including venture capital, equity as well as growth and business transition capital through its subsidiaries. The company was founded in 1995 and is headquartered in Montreal, Canada.

Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis.

Cytochroma, Inc. is a clinical-stage specialty pharmaceutical company. It develops and markets prescription products for the prevention of vitamin D insufficiency. The firm specializes in pharmaceutical products to treat and prevent secondary hyperparathyroidism associated with chronic kidney disease. The company was founded by Martin J. Petkovich in 1996 and is headquartered in Markham, Canada.